The trial will assess the disc’s safety and effectiveness for treating degenerative disc disease in patients with symptomatic conditions at two adjacent vertebral levels from C3 to C7, according to the release.
The study will involve 200 patients across up to 25 sites and will follow a multi-center, prospective, non-randomized, historically controlled design. All patients will receive the Synergy Disc and will be evaluated preoperatively, during surgery, immediately after surgery, and up to 24 months post-surgery.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
